Genetic testing for cancer susceptibility: The promise and the pitfalls

Nature Reviews Cancer

Volumn 4, Issue 3, 2004, Pages 235-241

  Lerman, Caryn ^a   Shields, Alexandra E ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GENETICS; CANCER MORTALITY; CANCER RISK; CANCER SUSCEPTIBILITY; FAMILIAL CANCER; GENE TARGETING; GENETIC ANALYSIS; GENETIC VARIABILITY; PRIORITY JOURNAL; RARE DISEASE; REVIEW;

EID: 1542410504     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1301     Document Type: Review

References (72)

1. American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J. Clin. Oncol. 21, 2397-2406 (2003).
2. Burke, W. Genetic testing. N. Engl. J. Med. 347, 1867-1875 (2002).
3. Isaacs, C., Peshkin, B. & Lerman, C. in Diseases of the Breast 2nd edn (eds Harris, J. R., Lippman, M. E., Morrow, M. & Osborne, C. K.) 237-354 (J. B. Lippincott, Philadelphia, 2000).
4. Biesecker, B. B. et al. Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. JAMA 269, 1970-1974 (1993).
5. Piepoli, A. et al. Linkage analysis identifies gene carriers among members of families with hereditary nonpolyposis colorectal cancer. Gastroenterology 110, 1404-1409 (1996).
6. Tambor, E. S., Rimer, B. K. & Strigo, T. S. Genetic testing for breast cancer susceptibility: awareness and interest among women in the general population. Am. J. Med. Genet. 68, 43-49 (1997).
7. Croyle, R. T. & Lerman, C. Interest in genetic testing for colon cancer susceptibility: cognitive and emotional correlates. Prev. Med. 22, 284-292 (1993).
8. Berth, H., Balck, F. & Dinkel, A. Attitudes toward genetic testing in patients at risk for HNPCC/FAP and the German population. Genet. Test. 6, 273-280 (2002).
9. Struewing, J. P., Lerman, C., Kase, R. G., Giambarresi, T. R. & Tucker, M. A. Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families. Cancer Epidemiol. Biomarkers Prev. 4, 169-173 (1995).
10. Lerman, C. et al. Genetic testing in families with hereditary nonpolyposis colon cancer. JAMA 281, 1618-1622 (1999).
11. Hadley, D. W. et al. Genetic counseling and testing in families with hereditary nonpolyposis colorectal cancer. Arch. Intern. Med. 163, 573-582 (2003).
12. Botkin, J. R. et al. Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am. J. Med. Genet. 118A, 201-209 (2003).
13. Biesecker, B. B. et al. Psychosocial factors predicting BRCA1/BRCA2 testing decisions in members of hereditary breast and ovarian cancer families. Am. J. Med. Genet. 93, 257-263 (2000).
14. Lerman, C. et al. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA 275, 1885-1892 (1996).
15. Meijers-Heiboer, H. et al. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J. Clin. Oncol. 21, 1675-1681 (2003).
16. Schwartz, M. D. et al. Spiritual faith and genetic testing decisions among high-risk breast cancer probands. Cancer Epidemiol. Biomarkers Prev. 9, 381-385 (2000).
17. Armstrong, K., Weiner, J., Weber, B. & Asch, D. A. Early adoption of BRCA1/2 testing: who and why. Genet. Med. 5, 92-98 (2003).
18. Sweet, K. M., Bradley, T. L. & Westman, J. A. Identification and referral of families at high risk for cancer susceptibility. J. Clin. Oncol. 20, 528-537 (2002).
19. Lodder, L. et al. Psychological impact of receiving a BRCA1/BRCA2 test result. Am. J. Med. Genet. 98, 15-24 (2001).
20. Meiser, B. et al. Psychological impact of genetic testing in women from high-risk breast cancer families. Eur. J. Cancer 38, 2025-2031 (2002).
21. Schwartz, M. D. et al. Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J. Clin. Oncol. 20, 514-520 (2002).
22. Lerman, C. et al. What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing. J. Clin. Oncol. 16, 1650-1654 (1998).
23. Cella, D. et al. A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire. Health Psychol, 21, 564-572 (2002).
24. Dorval, M. et al. Anticipated versus actual emotional reactions to disclosure of results of genetic tests for cancer susceptibility: findings from p53 and BRCA1 testing programs. J. Clin. Oncol. 18, 2135-2142 (2000).
25. Marteau, T. M. & Lerman, C. Genetic risk and behavioural change. BMJ 322, 1056-1059 (2001).
26. Peshkin, B. N. et al. Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing. Cancer Epidemiol. Biomarkers Prev. 11, 1115-1118 (2002).
27. Lerman, C. et al. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev. Med. 31, 75-80 (2000).
28. Schwartz, M. D. et al. Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 testing. J. Clin. Oncol. 21, 4034-4341 (2003).
29. Kauff, N. D. et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 346, 1609-1615 (2002).
30. Rebbeck, T. R. et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346, 1616-1622 (2002).
31. Sheppard, R., Fry, A., Rush, R., Steel, C. M. & Cutt, A. Women at risk of ovarian cancer: attitudes towards and expectations of the familial ovarian cancer clinic. Fam. Cancer 1, 31-37 (2001).
32. Schwartz, M. et al. Impact of BRCA1/BRCA2 counseling and testing in newly diagnosed breast cancer patients. J. Clin. Oncol. (in the press).
33. Meiser, B. et al. Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing hereditary breast cancer. J. Clin. Oncol. 18, 2250-2257 (2000).
34. van Dijk, S. et al. Genetic counselling and the intention to undergo prophylactic mastectomy: effects of a breast cancer risk assessment. Br. J. Cancer 88, 1675-1681 (2003).
35. Johnson, K. A., Trimbath, J. D., Petersen, G. M., Griffin, C. A. & Giardiello, F. M. Impact of genetic counseling and testing on colorectal cancer screening behavior. Genet. Test 6, 303-306 (2002).
36. Michie, S., Smith, J. A., Senior, V. & Marteau, T. M. Understanding why negative genetic test results sometimes fail to reassure. Am. J. Med. Genet. 119A, 340-347 (2003).
37. Beauchamp, T. L. & Walters, L. Contemporary Issues in Bioethics (Wadsworth Publishing Company, Belmont, CA, 1994).
38. U.S. Department of Labor, Department of Health and Human Services, Equal Employment Opportunity Commission and Department of Justice. Genetic It formation and the Workplace [online], (cited 21 Jan 2004). 〈 http://www.dol.gov/asp/programs/history/herman/reports/genetics.htm〉 (1998).
39. Goldman, J. Protecting privacy to improve health care. Health Aff. 17, 47-60 (1998).
40. Earnseliffe Research & Communications. Public Opinion Research into Biotechnology Issues: Third Wave. (Earnscliffe Research & Communications Ottawa, ON, 2000).
41. Fudson, K. L., Rothenberg, K. H., Andrews, L. B., Khan, M. J. E. & Collins, F. S. Genetic discrimination and health insurance: an urgent need for reform. Science 270, 391-393 (1995).
42. Lench, E. L., Doherty, R. J., Gaff, C. L., Macrae, F. A. & Lindeman, G. J. 'Cancer in the family' and genetic tosting: implications for life insurance. Med. J. Aust. 179, 480-483 (2003).
43. Electronic Privacy Information Center (U.S.) & Privacy International (U.K.). Privacy and Human Rights 2002: An international survey of privacy laws and developments. [online], (cited 21 Jan 2004), 〈 http://pi.greennet.org.uk/survey/phr2002/〉 (2002).
44. National Human Genome Research Institute. Policy and Legislation: Discrimination [online], (cited 29 Jan 2004), 〈 http://www.genome.gov/10002337#fedlnsDiscrim〉 (2004).
45. Department of Health (U.K.). Our inheritance, our future: realizing the potential of genetics in the NHS. [online], (cited 21 Jan 2004), 〈www.doh.gov.uk/genetics/whitepaper.htm〉 (2003).
46. Newman, B. et al. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 279, 915-921 (1998).
47. Diez, O. et al. Prevalence of BRCA1 and BRCA2 Jewish mutations in Spanish breast cancer patients. Br. J. Cancer 79, 1302-1303 (1999).
48. Shattuck-Eidens, D. et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 178, 1242-1250 (1997).
49. Woodage, T. et al. The APCI1307K allele and cancer risk in a community-based study of Ashkenazi Jews. Nature Genet. 20, 62-65 (1998).
50. Burchard, E. G. et al. The importance of race and ethnic background in biomedical research and clinical practice. N. Engl. J. Med. 348, 1170-1175 (2003).
51. Cooper, R. S., Kaufman, J. S. & Ward, R. Race and genomics. N. Engl. J. Med. 348, 1166-1170 (2003).
52. Risch, N., Burchard, E., Ziv, E. & Tang, H. Categorization of humans in biomedical research: genes, race and disease. Genome Biol. 3, comment2007.
53. Lehmann, L. S., Weeks, J. C., Klar, N. & Garber, J. E. A population-based study of Ashkenazi Jewish women's attitudes toward genetic discrimination and BRCA1/2 testing. Genet. Med. 4, 346-352 (2002).
54. King, P. A. in Gene Mapping: Using Law and Ethics as Guides (eds Annas, G. J. & Elias, S.) 94-111 (Oxford University Press, New York, 1992).
55. Bowman, J. & Murray, R Jr. Genetic Variation and Disorders in Peoples of African Origin (John Hopkins University Press, Baltimore, 1990).
56. Hards, R. et al. National Confidential Enquiry into counselling for genetic disorders by non-geneticists: general recommendations and specific standards for improving care. Br. J. Obstet. Gynaecol. 106, 658-663 (1999).
57. American Board of Genetic Counseling. Granting certification to qualified genetic counselors [online], (cited 29 Jan 2004), 〈 http://www.abgc.net/genetios/abgc/about/intro.shtml〉 (2003).
58. Collins, F. S. Preparing health professionals for the genetic revolution. JAMA 278, 1285-1286 (1997).
59. Emery, J., Watson, E., Rose, P. & Andermann, A. A systematic review of the literature exploring the role of primary care in genetic services. Fam. Pract. 16, 426-445 (1999).
60. Suchard, M. A., Yudkin, P. & Sinsheimer, J. S. Are general practitioners willing and able to provide genetic services for common diseases? J. Genet. Couns. 8, 301-311 (1999).
61. Brain, K., Soldan, J., Sampson, J. & Gray, J. Genetic counseling protocols for hereditary non-polyposis colorectal cancer: a survey of UK regional genetics centres. Clin. Genet. 63, 198-204 (2003).
62. Campbell, H. et al. Referrals of women with a family history of breast cancer from primary care to cancer genetics services in South East Scotland. Br. J. Cancer 89, 1650-1656 (2003).
63. Halman, C. A., Hankinson, S. E., Colditz, G. A., Hunter, D. J. & De Vivo, I. A polymorphism in CYP17 and endometrial cancer risk. Cancer Res. 61, 3955-3960 (2001).
64. Lerman, C. & Berrettini, W. Elucidating the role of genetic factors in smoking behavior and nicotine dependence. Am. J. Med. Genet. 118B, 48-54 (2003).
65. Rosmond, R., Bouchard, C. & Bjomtorp, P. 5-HT2A receptor gene promoter polymorphism in relation to abdominal obesity and cortisol. Obes. Res. 10, 585-589 (2002).
66. Comings, D. E., Muhleman, D. & Gysin, R. Dopamine D2 receptor (DRD2) gene and susceptibility to posttraumatic stress disorder: a study and replication. Biol. Psychiatry 40, 368-372 (1996).
67. Comings, D. E., Muhleman, D., Ahn, C., Gysin, R. & Flanagan, S. D. The dopamine D2 receptor gene: a genetic risk factor in substance abuse. Drug Alcohol Depend. 34, 175-180 (1994).
68. Shields, P. G. et al. Dopamine D4 receptors and the risk of cigarette smoking in African-Americans and Caucasians. Cancer Epidemiol. Biomarkers Prev. 7, 453-458.
69. Freedman, A. et al. US physicians' attitudes toward genetic testing for cancer susceptibility. Am. J. Med. Genet. 120A, 63-71 (2003).
70. Burke, W. & Emery, J. Genetics education for primary-care providers. Nature Rev. Genet. 3, 561-566 (2002).
71. Khoury, M. J., McCabe, L. L. & McCabe, E. R. Population screening in the age of genomic medicine. N. Engl. J. Med. 348, 50-58 (2003).
72. Peterson, E. A., Milliron, K. J., Lewis, K. E., Goold, S. D. & Merajver, S. D. Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population. Cancer Epidemiol. Biomarkers Preven. 11, 79-87 (2002).